# Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

> **NCT05291039** · NA · COMPLETED · sponsor: **Rehab Werida** · enrollment: 56 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT05291039
- **Lead sponsor:** Rehab Werida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-04-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291039, "Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT05291039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*